文献速递肝胆胰外科围术期管理与 ERAS

胰十二指肠切除术中颈部切缘评估的当代再评价

Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
PubMed 文献 · JAMA Surg · 2021-01-01

本文综述2000-2019年高质量回顾性研究,探讨胰十二指肠切除术中术中颈部切缘(IONM)阳性时追加切除的肿瘤学价值。最大规模多机构研究(1399例)显示,IONM阳性转为R0切除者与最终R1切除者中位生存相似(11.9 vs 13.7个月),均劣于R0切除(21个月)。IONM阳性可能是生物学侵袭性的替代指标,追加切除范围难以改善生存。

要点

  • IONM阳性追加切除至R0与最终R1切除者生存相似,均差于初始R0。
  • IONM阳性可能反映肿瘤生物学侵袭性,而非单纯解剖切缘问题。
  • 现有数据多未纳入现代新辅助化疗人群,切缘与化疗反应关系待探索。

核心结论

  • IONM阳性可能是生物学侵袭性的替代指标,追加切除范围不太可能改善生存。

研究设计与样本

  • 综述,批判性评价2000-2019年高质量回顾性研究,无随机临床试验。

主要发现

  • 最大规模多机构研究纳入1399例胰十二指肠切除术患者,R0切除(n=1196)中位生存21个月。
  • 最终R1切除(n=131)与IONM阳性转为R0切除(n=72)中位生存分别为13.7个月和11.9个月,相似。
  • 近期报告提示IONM转为R0切除或全胰腺切除可能与生存改善相关,但研究结果不一致。

临床怎么用

  • IONM阳性时追加切除至R0的肿瘤学获益不明确,应综合评估肿瘤生物学行为。
  • 多数研究未纳入现代联合化疗方案,切缘状态与化疗敏感性的关系需进一步研究。

局限性

  • 缺乏随机临床试验,证据主要来自回顾性研究。
  • 多数研究未包括接受现代联合化疗或新辅助化疗的患者。
  • 无专门数据指导IONM阳性且接受新辅助化疗患者的手术管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although margin-negative (R0) resection is the gold standard for surgical management of localized pancreatic ductal adenocarcinoma (PDAC), the question of how to manage the patient with a microscopically positive intraoperative neck margin (IONM) during pancreaticoduodenectomy remains controversial. OBSERVATIONS: In the absence of randomized clinical trials, we critically evaluated high-quality retrospective studies examining the oncologic utility of re-resecting positive IONMs during pancreaticoduodenectomy for PDAC (2000-2019). Several studies have concluded that additional pancreatic resection to achieve an R0 margin in IONM-positive cases does not influence survival. The largest is a multi-institutional study of 1399 patients undergoing pancreaticoduodenectomy, which demonstrated that in comparison with patients undergoing R0 resection (n = 1196; median survival, 21 months), those with either final R1 resections (n = 131) or undergoing margin conversion from IONM-positive to R0 resection on permanent section (n = 72) demonstrated similar median survival times (13.7 and 11.9 months, respectively). Conversely, recent reports suggest that the conversion of IONM to R0 resection with additional resection or even total pancreatectomy may be associated with improved survival. The discordance between these conflicting studies could be explained in part by the influence of biologic and physiologic selection on the association of IONM re-resection and survival. Since most studies did not include patients receiving modern combination chemotherapy regimens, the intersection between margin status, tumor biology, and chemoresponsiveness remains unclear. Furthermore, there are no dedicated data to guide surgical management in IONM-positive pancreaticoduodenectomy for patients receiving neoadjuvant chemotherapy. CONCLUSIONS AND RELEVANCE: Although data regarding the oncologic utility of additional resection to achieve a tumor-free margin following initial IONM positivity during pancreaticoduodenectomy for PDAC are conflicting, they suggest that IONM positivity may be a surrogate for biologic aggressiveness that is unlikely to be mitigated by the extent of surgical resection. The complex relationship between margin status and chemoresponsiveness warrants exploration in studies including patients receiving increasingly effective neoadjuvant chemotherapy.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Datta J, Willobee BA, Ryon EL, et al. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. JAMA Surg. 2021. PMID: 33533898. doi:10.1001/jamasurg.2020.5676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。